These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 3899758)

  • 1. [Anatomo-clinical presentation of graft-versus-host disease treated with cyclosporin A].
    Al Rustom K; Pierard-Franchimont C; Pierard GE
    Dermatologica; 1985; 171(2):65-71. PubMed ID: 3899758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
    Massumoto C; Benyunes MC; Sale G; Beauchamp M; York A; Thompson JA; Buckner CD; Fefer A
    Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporin A: use in preventing graft versus host disease.
    Klemm P
    Oncol Nurs Forum; 1985; 12(5):25-32. PubMed ID: 3898028
    [No Abstract]   [Full Text] [Related]  

  • 4. Overexpression of tissue inhibitor of metalloproteinases-3 in intestinal and cutaneous lesions of graft-versus-host disease.
    Salmela MT; Karjalainen-Lindsberg ML; Jeskanen L; Saarialho-Kere U
    Mod Pathol; 2003 Feb; 16(2):108-14. PubMed ID: 12591962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low incidence of severe acute and chronic graft-versus-host disease as a result of prolonged cyclosporine prophylaxis and early aggressive treatment with corticosteroids.
    Ruutu T; Volin L; Elonen E
    Transplant Proc; 1988 Jun; 20(3):491-3. PubMed ID: 3289191
    [No Abstract]   [Full Text] [Related]  

  • 6. Similarity between eruptions induced by sulfhydryl drugs and acute cutaneous graft-versus-host disease after bone marrow transplantation.
    Takatsuka H; Takemoto Y; Yamada S; Mori A; Wada H; Fujimori Y; Okamoto T; Kanamaru A; Kakishita E
    Hematology; 2002 Feb; 7(1):55-7. PubMed ID: 12171778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation.
    Crider MK; Jansen J; Norins AL; McHale MS
    Arch Dermatol; 1986 Sep; 122(9):1023-7. PubMed ID: 3527075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease.
    Russell JA; Woodman RC; Poon MC; Jones AR; Ruether BA
    Bone Marrow Transplant; 1994 Sep; 14(3):397-401. PubMed ID: 7994261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporin A-induced graft-versus-host disease following autologous bone marrow and stem cell transplantation in hematological malignancies of childhood.
    Gruhn B; Häfer R; Kosmehl H; Fuchs D; Zintl F
    Bone Marrow Transplant; 1998 May; 21(9):901-7. PubMed ID: 9613782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of cyclosporin A in 5 leukemia patients receiving allogeneic bone marrow transplantation].
    Akao Y; Sao H; Tahara T; Yoshikawa H; Yoshikawa S; Morishima Y; Hiraiwa A; Naoe T
    Rinsho Ketsueki; 1984 Sep; 25(9):1417-26. PubMed ID: 6394783
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of cyclosporine for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.
    Gluckman E; Devergie A; Lokiec F
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):461-9. PubMed ID: 3291282
    [No Abstract]   [Full Text] [Related]  

  • 12. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K; Downs K
    Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normal-looking skin in oncohaematological patients after allogenic bone marrow transplantation is not normal.
    Vassallo C; Brazzelli V; Alessandrino PE; Varettoni M; Ardigò M; Lazzarino M; Borroni G
    Br J Dermatol; 2004 Sep; 151(3):579-86. PubMed ID: 15377343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of graft versus host disease following allogeneic bone marrow transplantation.
    Powles RL; Goss GD; Millar J; Maitland J; Borthwick-Clark C; Al-Jundi A
    Tokai J Exp Clin Med; 1985 Jun; 10(2-3):133-8. PubMed ID: 3914738
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
    Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
    Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of the acute graft versus host skin reaction with cyclosporin and PUVA].
    Read D; Piérad GE; de la Brassinne M; Bury J
    Ann Dermatol Venereol; 1988; 115(4):427-31. PubMed ID: 3046456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J; Ringdén O
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporin-A in allogeneic bone marrow transplantation for leukemia: Basle experience 1979 to 1984.
    Gratwohl A
    Tokai J Exp Clin Med; 1985 Jun; 10(2-3):127-32. PubMed ID: 3914737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporin A (CsA): pharmacokinetics, clinical monitoring and pharmacodynamics in bone marrow transplantation (BMT).
    Carreras Pons E
    Prog Clin Biol Res; 1989; 309():325-32. PubMed ID: 2675101
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.